Viral Gastroenteritis Global Market Report 2024

The viral gastroenteritis market size has grown strongly in recent years. It will grow from $6.34 billion in 2023 to $6.7 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The expansion observed in the historical period can be attributed to several factors, including the prevalence of viral infections, global hygiene practices, advancements in diagnostics, increased global travel and tourism, and the impact of climate and environmental factors.

The viral gastroenteritis market size is expected to see steady growth in the next few years. It will grow to $8.1 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%. The anticipated growth in the forecast period for viral gastroenteritis can be attributed to factors such as global health preparedness, the impact of climate change, the adoption of a one health approach, the implementation of epidemiological surveillance systems, and increased education and public awareness. Key trends expected during the forecast period include advancements in vaccine development, the use of advanced diagnostics, the integration of telemedicine in diagnosis, collaborative research initiatives, the application of personalized medicine approaches, and the adoption of digital health solutions.

The projected increase in the prevalence of gastrointestinal disorders is set to drive the growth of the viral gastroenteritis market in the foreseeable future. Gastrointestinal (GI) disorders encompass diseases affecting any part of the gastrointestinal tract, and viral gastroenteritis drugs and diagnostic treatments play a crucial role in providing suitable medication for those afflicted with the condition. As per a survey report by Bodibio in October 2021, covering 73,076 adults across 33 countries, 40% of respondents reported having a functional gastrointestinal disorder, including variations such as functional dyspepsia, irritable bowel syndrome, and functional constipation. This underscores the escalating prevalence of gastrointestinal disorders and, consequently, the growth of the viral gastroenteritis market.

The growth of the viral gastroenteritis market is anticipated to be fueled by the increasing awareness surrounding hygiene and sanitation practices. Hygiene involves personal habits such as handwashing, waste disposal, and cleanliness, contributing to a clean environment, while sanitation pertains to ensuring safe waste disposal, water treatment, and maintaining hygienic surroundings. The emphasis on hygiene and sanitation plays a critical role in preventing the transmission of viruses causing gastroenteritis. These measures interrupt the fecal-oral route of transmission, reduce contamination, and contribute to overall community health. For instance, a survey conducted by Citron Hygiene in September 2022 revealed that, pre-pandemic, only 11% of individuals washed their hands for the recommended 18–20 seconds, but during the pandemic, this number increased to 25%. Moreover, 67% of respondents felt that the pandemic heightened their fear of germs and awareness of hygiene. Therefore, the growing awareness of hygiene and sanitation practices is a significant driver for the viral gastroenteritis market.

A prominent trend gaining momentum in the viral gastroenteritis market is product innovation. Major companies operating in this market are directing their efforts toward developing new products to fortify their market positions. For example, in November 2022, GlaxoSmithKline plc obtained approval from the US Food and Drug Administration (FDA) for an oral-dosing applicator-only presentation of ROTARIX, an oral vaccine to prevent rotavirus gastroenteritis in infants. This new presentation eliminates the need for reconstitution at the point of use, offering added convenience for healthcare providers. The approval is based on international clinical trial data demonstrating safety, tolerability, and immunogenicity compared to the lyophilized formulation.

Leading companies in the viral gastroenteritis market are introducing innovative products such as PCR kits for gastrointestinal infectious diseases to gain a competitive edge. PCR kits, also known as Polymerase Chain Reaction kits, are molecular biology tools designed for the amplification and detection of specific DNA sequences. For instance, in March 2023, Jiangsu Bioperfectus Technologies Co. Ltd. launched 10 Real Time PCR Kits designed for the accurate detection of gastrointestinal pathogens. Covering a range of bacterial, viral, and parasitic pathogens associated with gastrointestinal infections, this solution provides a streamlined approach from sample pre-processing to PCR amplification analysis.

In March 2021, Hologic, Inc. acquired Diagenode for $159 million, a move aimed at expanding and diversifying its diagnostic business. Diagenode, a Belgium-based diagnostic assay manufacturer, offers a comprehensive array of real-time PCR tests for detecting bacteria, parasites, and viruses involved in various infections, including gastroenteritis. This strategic acquisition positions Hologic to broaden its diagnostic capabilities across customer segments, test menus, and geography.

Major companies operating in the viral gastroenteritis market report are Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., AstraZeneca Plc., Abbott Laboratories, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG, Daiichi Sankyo Company Limited, Regeneron Pharmaceuticals Inc., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Bausch Health Companies Inc., Alexion Pharmaceuticals Inc., Horizon Therapeutics PLC, Dr. Reddy’s Laboratories Ltd., BioMarin Pharmaceutical Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Ironwood Pharmaceuticals Inc., ANI Pharmaceuticals Inc., Merck Sharp & Dohme Corp., Allergan PLC, Haustus Biotech Private Limited, Gracia Lifesciences India Private Limited.

North America was the largest region in the viral gastroenteritis market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral gastroenteritis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral gastroenteritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of drugs used in the treatment of viral gastroenteritis include antibiotics, antacids, laxatives, antimotility agents, and others. Antacids are medications that neutralize stomach acid to alleviate heartburn and indigestion. Diagnosis typically involves a physical examination and a rapid stool test, indicated by symptoms such as watery diarrhea, abdominal cramps, and pain. The various types of viruses associated with viral gastroenteritis include norovirus, rotavirus, astrovirus, and enteric adenovirus. These drugs and diagnostic procedures are utilized by various end-users, including hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers, and others.

The viral gastroenteritis market research report is one of a series of new reports that provides viral gastroenteritis market statistics, including viral gastroenteritis industry global market size, regional shares, competitors with a viral gastroenteritis market share, detailed viral gastroenteritis market segments, market trends, and opportunities, and any further data you may need to thrive in the viral gastroenteritis industry. This viral gastroenteritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The viral gastroenteritis market consists of revenues earned by entities by providing various diagnostics such as polymerase chain reaction testing and immunoassays. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral gastroenteritis market also includes sales of antiemetics, and chemotherapy drugs used for treating viral gastroenteritis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.